RBC Capital analyst Leonid Timashev reiterated an Outperform rating on Legend Biotech but reduced the price target from $63 to $59. This indicates a slightly less optimistic outlook on the stock's near-term valuation, despite maintaining a positive overall recommendation.
RBC Capital's decision to lower Legend Biotech's price target from $63 to $59, while maintaining an 'Outperform' rating, signals a nuanced view. This adjustment suggests that while the analyst still believes in the company's long-term potential, there might be new short-term headwinds or a recalibration of valuation metrics. This could lead to some negative sentiment among investors, potentially causing a slight dip in LEGN's stock price in the short term. However, the maintained 'Outperform' rating indicates that the analyst still sees significant upside from the current price, offering a potential buying opportunity for long-term investors if the stock dips.